BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12643012)

  • 1. Developments in the systemic therapy of pancreatic cancer.
    el-Rayes BF; Shields AF; Vaitkevicius V; Philip PA
    Cancer Invest; 2003; 21(1):73-86. PubMed ID: 12643012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):426-36. PubMed ID: 12647986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer: the evolving role of systemic therapy.
    Adsay NV; El-Rayes BF; Philip PA
    Expert Opin Pharmacother; 2001 Dec; 2(12):1939-47. PubMed ID: 11825326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
    Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
    [No Abstract]   [Full Text] [Related]  

  • 5. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
    Kozuch P; Petryk M; Bruckner HW
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):123-38. PubMed ID: 12063823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
    Twombly R
    J Natl Cancer Inst; 2008 Dec; 100(23):1670-1. PubMed ID: 19033566
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging drugs in pancreatic cancer.
    Ducreux M; Boige V; Malka D
    Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locally advanced pancreatic cancer.
    Oikonomopoulos GM; Huber KE; Syrigos KN; Saif MW
    JOP; 2013 Mar; 14(2):126-8. PubMed ID: 23474552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
    André T; Balosso J
    J Chir (Paris); 1999 Dec; 136(6):309-17. PubMed ID: 10675820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and future treatment of pancreatic cancer.
    Heinemann V
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):23-31. PubMed ID: 12094335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gemcitabine-based combinations in inoperable pancreatic cancers].
    Louvet C; André T; Artru P
    Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of locally advanced adenocarcinoma of the pancreas.
    Ryan DP; Willett CG
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):95-103. PubMed ID: 12063831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
    Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
    Abbruzzese JL
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):2-8. PubMed ID: 12577227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and platinum combinations in pancreatic cancer.
    Philip PA
    Cancer; 2002 Aug; 95(4 Suppl):908-11. PubMed ID: 12209670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
    Fujita T
    JAMA; 2008 Jun; 299(24):2852; author reply 2852-3. PubMed ID: 18577725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.